ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2771

Current Practice of Cardiovascular Risk Assessment in Giant Cell Arteritis: A Single Center Study

Mohammed Bari1, Anthony Ocon2, Mohamed Tageldin1, Mirrah Mumtaz1, Muhammad Saad Shaukat1, Paul Feustel1, Ruben Peredo2, Peter C. Grayson3 and Shubhasree Banerjee1,4,5, 1Albany Medical Center, Albany, NY, 2Medicine, Albany Medical Center, Albany, NY, 3National Institute of Arthritis, Musculoskeletal and Skin Disease, National Institutes of Health, Bethesda, MD, 4The Center for Rheumatology, Albany, NY, 5Systemic Autoimmunity Branch, NIAMS, NIH, Bethesda, MD

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Cardiovascular disease, giant cell arteritis and prevention

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, October 23, 2018

Title: Vasculitis Poster III: Immunosuppressive Therapy in Giant Cell Arteritis and Polymyalgia Rheumatica

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose:

Giant cell arteritis (GCA) is a large vessel vasculitis affecting individuals over 50 years of age. Multiple epidemiological studies have determined increased risk of cardiovascular diseases (CVD) in GCA. There are no guidelines to assess CV risk in GCA. The study objective was to review current practice of monitoring CV risk in GCA by rheumatologists in a single center academic rheumatology practice.

Methods:

Retrospective chart review of patients diagnosed with GCA was conducted. Data included demographics, comorbid conditions including CVD, obesity, diabetes mellitus (DM), hypertension (HTN), hyperlipidemia (HLD), tobacco use, and physician intervention for CV risk reduction which was defined as measuring lipid profile (LP), use of antiplatelet agent, smoking cessation counseling, lifestyle modification counseling defined as education on healthy diet, exercise, and weight loss. LP measurement was either done at rheumatologists’ office or documented as done outside by primary care physician or cardiologist. We used backward elimination logistic regression to assess associations between the likelihood of physician intervention for CV risk reduction, with respect to age, gender, presence or absence of CV risk factors (BMI, tobacco use, DM, HTN, HLD), and prior CVD. HLD was defined as per American College of Cardiology 2013 guidelines.

Results:

148 patients with GCA were seen from 2008 – 2017. The majority of patients were female (111, 75%) with median age of 75 (range 51-93) years. Prevalence of HTN, HLD, CVD, and DM was 72% (n=106), 53% (n=79), 34% (n=50), and 21% (N=31), respectively. Few patients were active smokers (13, 9%) but many were overweight/obese (93, 64%). LP was assessed at least once in only 18% (n=26) patients, and 43% (n=63) were taking a statin. 67% (n=99) patients were on antiplatelet or anticoagulation (AC) therapy. Lifestyle modification counseling was documented in 45% (n=67) patients. Smoking cessation was discussed in 31% smokers. Among the patients with prior CVD, 82% (n=41) were on antiplatelet/AC; 14% (n=7) had LP assessed; and lifestyle modification counseling was documented in 36% (n=18). Male gender and high BMI were associated with higher likelihood of lifestyle modification counseling, (OR 3.4; 95% CI 1.2-10.2) and (OR 1.16; CI 1.1-1.3), respectively. Measuring LP was more common in men (OR 5.2; 95% CI 1.4-19.5) and in subjects with HLD (OR 32.1; 95% CI 6.0-172.1).

Conclusion:

This single center study identified potential areas of improvement in the monitoring of CV risk in patients with GCA. Assessment of lipid profile, lifestyle modification counseling, and smoking cessation were infrequently performed or documented in patients with GCA. The likelihood of physician intervention for CV risk reduction was associated with presence of traditional CV risk factors rather than consideration of GCA as a strong independent risk for CVD. Developing guidelines to monitor CV risk in GCA will be useful for clinicians and may help to reduce CV morbidity and mortality in this population.


Disclosure: M. Bari, None; A. Ocon, None; M. Tageldin, None; M. Mumtaz, None; M. Saad Shaukat, None; P. Feustel, None; R. Peredo, None; P. C. Grayson, None; S. Banerjee, None.

To cite this abstract in AMA style:

Bari M, Ocon A, Tageldin M, Mumtaz M, Saad Shaukat M, Feustel P, Peredo R, Grayson PC, Banerjee S. Current Practice of Cardiovascular Risk Assessment in Giant Cell Arteritis: A Single Center Study [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/current-practice-of-cardiovascular-risk-assessment-in-giant-cell-arteritis-a-single-center-study/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/current-practice-of-cardiovascular-risk-assessment-in-giant-cell-arteritis-a-single-center-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology